Their drugable pathway involves MEK inhibition whi

Quote:

---

Their drugable pathway involves MEK inhibition which is downregulated by Leronlimab per OHM…interesting to note that direct approach’s to inhibition seem to be associated with significant side effects.

---

Another example of a very high level of downregulation (via MEK inhibitors) inducing bad side effects vs. leronlimab downregulating overexpression to a more normal level by allowing other CCR receptor activity to continue.